hVIVO (LON:HVO) Stock Price Up 23% - What's Next?

hVIVO plc (LON:HVO - Get Free Report) shares were up 23% during mid-day trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). Approximately 24,253,932 shares were traded during trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Wall Street Analyst Weigh In

Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Stock Performance

The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The business's 50 day simple moving average is GBX 15.92 and its 200 day simple moving average is GBX 17.70. The company has a market cap of £73.59 million, a P/E ratio of 4.29 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Sell-side analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insider Activity at hVIVO

In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($705,491.02). 14.03% of the stock is currently owned by insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.